Cytodyn Inc (CYDY)

[Borel Fields]

OK, getting the sense of the other Figure 2 graphs.

(b) and (c) go together - (b) shows CD8 recovery relative to all CD cells "3 or higher" while (c) shows recovery relative specifically to CD4. Both show normalization of the immune system. Both statistically significant.

(d) and (e) go together, telling the story of CCR5 "receptor occupancy" - (c) looks at bulk T-cells and (e) at monocytes. This is a "relative binding" number as I read it. I believe these two charts are where make BP makes his case that leronlimab's preferential binding to CCR5 is the causal factor in improvements. Can someone help here?